[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-associated-ophthalmopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-associated-ophthalmopathy":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,71,91,117,149,173,197,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100434417","phase-2-sirolimus-vs-corticosteroids-in-treatment-of-thyroid-eye-disease-100434417",false,"NCT04936854","Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease","Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease","Inclusion Criteria:\n\n* The participant want treatment for active thyroid eye disease and is willing to be included in the study\n* Clinical diagnosis of Graves' disease associated with active TED with a Clinical Activity Score (CAS) ≥ 4 (on the 7-item scale)\n* Moderate-to-severe active TED (not sight-threatening but has an appreciable impact on daily life), usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and\u002For inconstant or constant diplopia\n* Onset of active TED symptoms (as determined by participant records) within 9 months prior to inculsion\n* Participants must be euthyroid with the Graves disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine and free triiodothyronine levels \\\u003C 50% above or below the normal limits).\n* Does not require immediate surgical ophthalmological intervention and is not planning corrective surgery\u002Firradiation during the course of the study\n* Diabetic participants must have well-controlled stable disease (defined as HbA1C \\\u003C 9.0% with no new diabetic medication \\[oral or insulin\\] or more than a 10% change in the dose of a currently prescribed diabetic medication within 60 days prior to Screening)\n* Women of childbearing potential (including those with an onset of menopause \\\u003C2 years prior to Screening, non-therapy-induced amenorrhea for \\\u003C12 months prior to Screening, or not surgically sterile \\[absence of ovaries and\u002For uterus\\]) must have a negative serum pregnancy test at Screening and negative urine pregnancy tests at all protocol-specified timepoints (i.e., prior to each dose and through Week 48 of the Follow-Up Period); participants who are sexually active with a non-vasectomized male partner must agree to use 2 reliable forms of contraception during the trial, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started at least one full cycle prior to Baseline and continue for 180 days after the last dose of study drug. Highly effective contraceptive methods (with a failure rate less than 1% per year) when used consistently and correctly, includes implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence or vasectomized partner\n* Male participants must be surgically sterile or, if sexually active with a female partner of childbearing potential, must agree to use barrier contraceptive method from Screening through 180 days after the last dose of study drug\n* Active Influenza and Pneumococcal vaccines\n\nExclusion Criteria:\n\n* The participant dont want treatment for active thyroid eye disease or dont want to participate in the study\n* Decreased vision due to optic neuropathy as defined by a significant decrease in best corrected visual acuity, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months\n* Corneal decompensation unresponsive to medical management\n* Previous orbital irradiation or surgery for TED Any steroid use (intravenous \\[IV\\] or oral) with a cumulative dose equivalent to ≥ 1 g of methylprednisolone for the treatment of TED. Previous steroid use (IV or oral) with a cumulative dose of \\\u003C1 g methylprednisolone or equivalent for the treatment of TED and previous use of steroid eye drops is allowed if the corticosteroid was discontinued at least 4 weeks prior to inclusion\n* Corticosteroid use for conditions other than TED within 4 weeks prior to inclusion (topical steroids for dermatological conditions and inhaled steroids are allowed)\n* Selenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during the clinical trial; however, taking a multivitamin that includes selenium and\u002For biotin is allowed\n* Use of any other non-steroid immunosuppressive including agent, new biologic drugs within 3 months prior to Screening\n* Use of an investigational agent for any condition within 60 days prior to inclusion or anticipated use during the course of the trial\n* Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude study participation or complicate interpretation of study results\n* Bleeding diathesis that in the judgment of the Investigator would preclude inclusion in the clinical trial\n* Malignant condition in the past 12 months (except successfully treated basal\u002Fsquamous cell carcinoma of the skin)\n* Pregnant or lactating women\n* Current drug or alcohol abuse, or history of either within the previous 2 years, in the opinion of the Investigator or as reported by the participant\n* Biopsy-proven or clinically suspected inflammatory bowel disease\n* Known hypersensitivity to any of the components Sirolimus.\n* Any other condition that, in the opinion of the Investigator, would preclude inclusion in the study\n* Previous enrollment in this study\n* Human immunodeficiency virus (HIV), tuberculosis, hepatitis C or hepatitis B infections","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to determine whether Sirolimus is more effective and burdened with less side effects than conventional treatment with corticosteroids in patients with active thyroid eye disease.",[27],"Thyroid-Associated Ophthalmopathy",[29,30,31,32,33],"Thyroid eye disease","Graves' Orbitopathy","Immunosuppressive Agents","Exophthalmos","Sirolimus","RECRUITING","2025-09-19",{"date":37,"type":38},"2025-09-22","ACTUAL",{"date":40,"type":38},"2023-01-01",{"date":42,"type":21},"2028-12",{"name":44,"class":45},"Haukeland University Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100602519","construction-and-application-of-precise-diagnosis-and-treatment-system-for-thyroid-associated-ophthalmopathy-100602519","NCT07124572","Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy","Inclusion Criteria:\n\n* normal participants without eyelid disorders (control group)\n* patients with thyroid-associated ophthalmopathy (TAO group)\n* cooperative participants\n\nExclusion Criteria:\n\n* participants with pupil or cornea disorders\n* participants with history of eye injury",true,"7 Years","90 Years",{"count":57,"type":21},500,"OBSERVATIONAL","This study aims to develop the deep learning-based system that integrates multimodal information to automatically diagnose, stage, and grade thyroid-associated ophthalmopathy (TAO), assist in treatment decision-making, and predict patient prognosis, thereby providing novel tools to support clinical management.",[61],"Thyroid Associated Ophthalmopathy","2025-08-13",{"date":64,"type":38},"2025-08-15",{"date":66,"type":38},"2022-10-01",{"date":68,"type":21},"2031-10-01",{"name":70,"class":45},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":78,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":46},"100561442","establishment-of-multiparametric-prediction-models-for-moderate-to-severethyroid-associated-ophthalmopathy-100561442","NCT06590220","Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy","Establishment of Multiparametric Prediction Models for Moderate to Severe Thyroid Associated Ophthalmopathy","Inclusion Criteria:\n\n* According to the Bartley criteria，diagnosed TAO at our hospital after 2024\u002F8\u002F31\n* Moderate to severe patients defined by EUGOGO\n* CAS ≥3 (on the 7-item scale) for the study eye\n\nExclusion Criteria:\n\n* Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision\n* History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \\>1 g of methylprednisolone for the treatment of TAO.\n* Any major illness\u002Fcondition or evidence of an unstable clinical condition that, in the investigator\\'s judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study\n* Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participant\\'s participation in the study\n* Pregnant or lactating\n* Any other condition that,would impair the ability of the participant to undergo orbital MRI\n* Incomplete information",{"count":79,"type":21},150,"Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO.\n\nThe aim of this clinical study is to:\n\n1. Found the new diagnostic markers or imaging sequences.\n2. Establish and validate a multimodal and multiparameter prediction model for moderate to severe TAO.",[61],"2025-06-21",{"date":84,"type":38},"2025-06-24",{"date":86,"type":38},"2024-10-09",{"date":88,"type":21},"2028-09-06",{"name":90,"class":45},"Shanghai Changzheng Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":46},"100587360","phase-4-a-study-on-the-combined-use-of-tocilizumab-and-flupentixol-melitracen-in-the-treatment-of-thyroid-associated-ophthalmopathy-100587360","NCT06927375","A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","Clinical Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy: A Prospective Exploratory Study","Inclusion Criteria:\n\n* Aged between 18 and 80 years (inclusive).\n* Meets internationally recognized diagnostic criteria for TED with the more severely affected eye in moderate to severe active phase. Meeting any one of the following criteria qualifies as moderate to severe: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm. A Clinical Activity Score (CAS) of ≥3 or a score of 2 combined with MRI evidence indicating active disease is defined as active.\n* Normal thyroid function within one month prior to enrollment: including those currently taking antithyroid drugs or not requiring medication, with FT3 and FT4 levels within normal range and TSH either normal or decreased.\n* HAMA (Hamilton Anxiety Rating Scale) score of ≥14.\n* Voluntary participation and provision of informed consent.\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, or renal insufficiency (including myocardial ischemia or myocardial infarction, arrhythmias, and heart failure; ALT, AST ≥ 3 times the upper limit of normal; eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m²).\n* communicable disease.\n* Pregnancy or planning to become pregnant.\n* Currently breastfeeding.\n* Received radioactive iodine treatment or hepatitis vaccination within three months prior to enrollment.\n* Received systemic immunotherapy for TAO, including oral or intravenous glucocorticoids, other immunosuppressants, or orbital radiotherapy within one month prior to enrollment.\n* Planning to undergo other treatments during the course of this study.\n* Severe mental disorders that affect compliance.\n* Presence of other clinically significant or unstable systemic diseases.\n* Patients who are unlikely to complete the entire course of treatment.",{"count":20,"type":21},[100],"PHASE4","Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity. The activity of TAO is commonly evaluated using the Clinical Activity Score (CAS). Tocilizumab serves as a second-line treatment option for patients with moderate to severe active TAO. Additionally, it is common for TAO patients to experience anxiety, which may exacerbate their condition and negatively impact prognosis. Therefore, we have designed this randomized controlled study to evaluate the impact of Flupentixol Melitracen (Lepan) on the treatment outcomes of participants receiving Tocilizumab (Actemra).",[27],[104,105,61,106,107],"Thyroid Eye Disease","Graves Orbitopathy","TAO","TED","2025-04-14",{"date":110,"type":38},"2025-04-16",{"date":112,"type":38},"2024-12-12",{"date":114,"type":21},"2026-03-12",{"name":116,"class":45},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":148},"100524715","phase-2-extension-study-of-two-doses-of-linsitinib-in-subjects-with-active-moderate-to-severe-thyroid-eye-disease-ted-100524715","NCT06112340","Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","Inclusion Criteria:\n\n* Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (\\\u003C 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301\n* Subject has not received any treatment for TED since Week 24 of VGN-TED-301\n* Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \\[FT4\\] and free triiodothyronine levels \\[FT3\\] \\\u003C50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial\n* Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study\n\nExclusion Criteria:\n\n* The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.",{"count":125,"type":21},75,[24,127],"PHASE3","The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.",[104,105,130,131,61,132,133,134,135,136,32,137],"Endocrine System Diseases","Eye Diseases","Graves Ophthalmopathy","Thyroid Diseases","Orbital Diseases","Proptosis","IGF1R","Hashimoto","2025-02-24",{"date":140,"type":38},"2025-02-25",{"date":142,"type":38},"2023-10-11",{"date":144,"type":21},"2026-06",{"name":146,"class":147},"Sling Therapeutics, Inc.","INDUSTRY",2,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":46},"100546282","phase-3-orbital-radiotherapy-in-graves-ophthalmopathy-1-week-vs-2-weeks-orago-1-trial-100546282","NCT06392906","Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)","Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks: A Phase II Randomized Controlled Trial (OraGO-1 Trial)","Inclusion Criteria:\n\n* Patient with active moderate to severe thyroid eye disease with a CAS \\> 4 with\u002F without diplopia before starting IVMP\n* Patient with poor response to 3 doses of IVMP (CAS drop \\\u003C 1) หรือ CAS score \\> 3 after 3 doses of IVMP\n* Patients with diplopia after 3 doses of IVMP\n* Patients with Graves' Ophthalmopathy who have maintained euthyroidism\n* Non-pregnant adults (aged 35 years or older)\n\nExclusion Criteria:\n\n* Individuals with severe hypertension or diabetic retinopathy","70 Years",{"count":158,"type":21},68,[127],"Thyroid ophthalmopathy, also known as thyroid eye disease or Graves' ophthalmopathy, is a condition characterized by inflammation and swelling of the tissues around the eyes, often accompanied by protrusion of the eyeballs. This condition can lead to significant discomfort, visual disturbances, and in severe cases, permanent vision loss.\n\nPrimary treatment modalities are intravenous methylprednisolone (IVMP) and other medications for patients with moderate to severe and active thyroid eye disease. In addition, external beam radiation therapy (ERT) is an another treatment option in combination with IVMP.\n\nRadiation therapy delivers targeted doses of ionizing radiation to the affected orbital tissues, effectively reducing inflammation. This approach is particularly beneficial for patients who may not respond adequately to steroid therapy alone or those who experience recurrent disease flares.\n\nThis study will test the efficacy of a shortened treatment regimen comprising 5 sessions of ERT to a standard protocol of 10 treatments. The primary aim is to ascertain the effectiveness of shorted radiation treatment while improving patients' quality of life.",[61],[163],"radiation therapy","2024-12-01",{"date":166,"type":38},"2024-12-04",{"date":168,"type":38},"2024-07-11",{"date":170,"type":21},"2028-10-31",{"name":172,"class":45},"Janjira Petsuksiri",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":46},"100295884","phase-3-treatment-of-gravesophthalmopathy-with-simvastatin-go-s-100295884","NCT03131726","Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)","Inclusion Criteria:\n\n1. Age 18-70 years\n2. Active mild to moderate with at least one sign of mild GO (NO SPECS class 2a and b) with reference to Colour Atlas at EUGOGO website (www.eugogo.eu). Exophthalmos up to 24 mm with a disease duration of \\\u003C18 months (as recorded by the patient)\n3. Graves´ disease with clinical and laboratory euthyroidism after stopping treatment with anti thyroid drugs (ATD), or 2 months treatment with ATD, or euthyroid 6 months after treatment with radioiodine, or euthyroid after total thyroidectomy. Clinical and laboratory euthyroidism is defined as normal fT4, fT3 and TSH below the upper limit of the local reference interval and no clinical symptoms or signs of hyperthyroidism. L-thyroxine is used to achieve euthyroidism during the study period.\n\nExclusion Criteria:\n\n1. Pregnancy or breast-feeding\n2. Previous treatment of Graves´ ophthalmopathy\n3. Severe Graves ophthalmopathy requiring corticosteroid treatment, retrobulbar irradiation, orbital decompression surgery\n4. Current or previous treatment with simvastatin or other statins (within 3 months)\n5. Allergy (skin rash or systemic reactions) to statins\n6. Congestive heart failure\n7. Renal insufficiency (glomerular filtration rate \\\u003C60 ml\u002Fmin)\n8. ASAT or ALAT \\> 2.5 times the upper limit of the local laboratory\n9. Alcoholism as judged by local criteria\n10. Coagulopathy including treatment with warfarin or new oral anti-coagulation drugs\n11. Previous or current gastric ulcer\n12. Inflammatory bowel disease diabetic retinopathy or nephropathy\n13. Trauma within 10 days",{"count":180,"type":21},80,[127],"In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy treated with simvastatin or no treatment.",[132,61,184],"Thyroid Associated Orbitopathy",[186,187],"simvastatin","diclofenac","2024-09-23",{"date":190,"type":38},"2024-09-25",{"date":192,"type":38},"2018-01-26",{"date":194,"type":21},"2028-03-30",{"name":196,"class":45},"Lund University",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":46},"100447882","multi-model-image-of-doxycycline-in-tao-100447882","NCT05112211","Multi-model Image of Doxycycline in TAO","A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy","Inclusion Criteria:\n\n* Informed consent\n* Age 18-70 years old\n* Diagnosed with TAO\n\nExclusion Criteria:\n\n* Sight-threatening TAO with dysthyroid optic neuropathy\n* Allergy of tetracycline\n* Have contraindications of MRI(metal pacemaker, fake teeth, foreign body and other materials which will disturb the examination)",{"count":205,"type":21},20,[207],"NA","This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated Ophthalmopathy by multi-modal image.",[61],[211,61,212,213,214],"Doxycycline","Extraorbital muscle","Orbit fat volume","Multi-modal image","2023-11-21",{"date":217,"type":38},"2023-11-22",{"date":219,"type":38},"2022-01-01",{"date":221,"type":21},"2026-12-01",{"name":223,"class":45},"Sun Yat-sen University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100293313","phase-4-a-trial-to-evaluate-the-efficacy-of-orbital-radiotherapy-in-graves-orbitopathy-100293313","NCT03098225","A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy","A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy","ORGO","Inclusion Criteria:\n\n1. A diagnosis of Graves' disease based on the presence of hyperthyroidism (either untreated or treated with antithyroid drugs) associated with detectable anti-TSH receptor autoantibodies\n2. No major treatments for hyperthyroidism (thyroidectomy or radioiodine) in the last 3 months\n3. Euthyroidism on anti-thyroid medications or L'thyroxine (LT4) since at least 2 months\n4. GO symptoms lasting since no more than one year\n5. Active GO: CAS ≥ 3 out of 7 (worst eye)\n6. Moderate or moderately severe GO: at least one of the following signs (worst eye):\n\n   * Exophthalmos ≥ 22 mm\n   * Eye muscle involvement with mono-ocular ductions in any direction of gaze of less than 30° or evident dismotility\n   * Diplopia according to Gorman score of grades a-c\n7. No corticosteroids or immunosuppressive treatment for GO in the last 3 months\n8. No contraindication to OR: diabetes, hypertension, retinopathy of any type, glaucoma\n9. Male and female patients of age: 35-75 years\n10. Effective method of contraception during the whole trial and at least six weeks after last intake of trial drugs (only female of reproducing age)\n11. No mental illness that prevent patients from comprehensive, written informed consent\n12. Compliant patient, regular follow-up possible\n\nExclusion Criteria:\n\n1. Absence of Graves' hyperthyroidism (present or past)\n2. Thyroidectomy or radioiodine in the last 3 months\n3. Uncontrolled hyperthyroidism or hypothyroidism\n4. GO symptoms lasting since more than one year\n5. CAS \\\u003C3 (worst eye)\n6. Optic neuropathy\n7. Contraindications to OR (diabetes, retinopathy of any kind)\n8. Pregnancy, breast-feeding women\n9. No informed consent\n10. Acute or chronic liver disease\n11. Relevant Malignancy\n12. Chronic renal failure or other diseases of any relevance to prevent steroid treatment 13) Corticosteroids or other immunosuppressive agents within last 3 months\n13. Recent (≤1 year) history of alcoholism or drug abuse\n14. Previous orbital disease other than GO, eye injuries or surgery","35 Years","75 Years",{"count":235,"type":21},120,[100],"Graves' orbitopathy (GO) is a disfiguring and disabling disease that profoundly impairs the quality of life of affected patients. High dose intravenous (iv) glucocorticoids (GC) (ivGC) is a well established, widely used treatment for active GO. The use of systemic glucocorticoids takes advantage from their immune suppressive and antiinflammatory actions, resulting in an overall beneficial effect ranging from \\~35 to \\~60% of patients in various studies. The intravenous route of administration has been shown to be superior to the oral route, both in terms of GO outcome and side effect profile. The combination of ivGC and orbital radiotherapy (OR) is used routinely in patients with moderate-severe, active GO, as a second-line treatment, as also recommended in the recent Guidelines published by the European Thyroid Association\u002FEuropean Group on Graves' Orbitopathy. Thus, the majority of studies have shown that OR increases the response rate to GC. Those studies were performed using oral GC, whereas it is not known whether OR potentiate also the effects of ivGC.\n\nThe present study is aimed at determining whether OR potentiate the effects of ivGC in the treatment of moderately severe and active GO, in terms of GO outcome and quality of life. A possible extension of the study can be foreseen, aimed at investigating the very long time GO outcome.",[61],"NOT_YET_RECRUITING","2023-03-14",{"date":242,"type":38},"2023-03-15",{"date":244,"type":21},"2024-01-01",{"date":246,"type":21},"2027-03-31",{"name":248,"class":45},"University of Pisa"]